Arcellx raises $115M to advance controllable cell therapies

By The Science Advisory Board staff writers

April 13, 2021 -- Arcellx has raised $115 million to advance its pipeline of adaptive and controllable cell therapies.

Proceeds from the financing will support the company's development of a B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR)-modified T-cell therapy called CART-ddBCMA. The agent is currently in a phase I clinical trial for the treatment of relapsed and refractory multiple myeloma and is expected to begin a pivotal trial in 2022.

Furthermore, the funding will support the initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from the company's controllable ARC-SparX platform. This agent is targeted at the treatment of multiple myeloma and acute myelogenous leukemia, respectively.

The series C financing was co-led by Samsara BioCapital and CAM Capital.

Copyright © 2021

BioTech Pharma Summit
September 27-28
Porto Portugal
Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter